Top

Published in:

01-02-2019 | Lung Cancer | Research Paper

Sema4D expression and secretion are increased by HIF-1α and inhibit osteogenesis in bone metastases of lung cancer

Authors: Wu-gui Chen, Jing Sun, Wei-wei Shen, Si-zhen Yang, Ying Zhang, Xu Hu, Hao Qiu, Shang-cheng Xu, Tong-wei Chu

Published in: Clinical & Experimental Metastasis | Issue 1/2019

Abstract

Most lung cancer bone metastasis are characterized by osteolytic destruction and osteoblastic activity is significantly decreased, suggesting that hypoxia may play a critical role in the process, but the underlying mechanisms remain unknown. Semaphorin 4D (Sema4D) is a recently discovered osteogenic inhibitory factor that is expressed at high levels in lung cancers. Here, CoCl₂-induced hypoxia significantly enhanced the inhibitory effect of lung cancer cell conditioned media on osteoblast differentiation by inducing the expression and secretion of Sema4D in a HIF-1α- but not HIF-2α-dependent manner. Moreover, HIF-1α directly regulated Sema4D expression by binding to bases 1171 to 798 in the Sema4D promoter. Furthermore, hypoxia increased Sema4D secretion by upregulating a disintegrin and metalloproteinase 17 (ADAM17) expression in lung cancer in a HIF-1α-dependent manner. In bone metastasis samples from 49 patients with lung cancer, Sema4D and ADAM17 expression significantly correlated with HIF-1α expression and strongly correlated with a poor differentiation status and osteolytic bone destruction. These results provide the first evidence that HIF-1α-induced Sema4D expression and secretion play important roles in lung cancer osteolytic bone metastasis by inhibiting osteoblast differentiation, thereby providing potential strategies for the treatment of bone metastasis via targeting osteoblasts.

Available only for authorised users

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA 66(2):115. https://doi.org/10.3322/caac.21338 CrossRef

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA 65(1):5–29. https://doi.org/10.3322/caac.21387 CrossRef

Coleman RE (1997) Skeletal complications of malignancy. Cancer 80 (8 Suppl):1588–1594CrossRef

Rove KO, Crawford ED (2009) Metastatic cancer in solid tumors and clinical outcome: skeletal-related events. Oncology 23(5):21–27PubMed

Yang Y, Ma Y, Sheng J, Huang Y, Zhao Y, Fang W, Hong S, Tian Y, Xue C, Zhang L (2016) A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China. Chin J Cancer 35(5):223–228. https://doi.org/10.1186/s40880-016-0102-6 CrossRef

Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466(3):729–736. https://doi.org/10.1007/s11999-007-0051-0 CrossRefPubMedPubMedCentral

Tang Y, Qu J, Wu J, Liu H, Chu T, Xiao J, Zhou Y (2016) Effect of surgery on quality of life of patients with spinal metastasis from non-small-cell lung cancer. J Bone Joint Surg Am 98(5):396–402. https://doi.org/10.2106/jbjs.o.00629 CrossRefPubMed

Gdowski AS, Ranjan A, Vishwanatha JK (2017) Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res 36(1):108. https://doi.org/10.1186/s13046-017-0578-1 CrossRefPubMedPubMedCentral

Suva LJ, Washam C, Nicholas RW, Griffin RJ (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7(4):208. https://doi.org/10.1038/nrendo.2010.227 CrossRefPubMedPubMedCentral

10.

Clézardin P (2017) Pathophysiology of bone metastases from solid malignancies. Joint Bone Spine Revue Du Rhumatisme. https://doi.org/10.1016/j.jbspin.2017.05.006 CrossRef

11.

Wu MY, Li CJ, Yiang GT, Cheng YL, Tsai AP, Hou YT, Ho YC, Hou MF, Chu PY (2018) Molecular regulation of bone metastasis pathogenesis. Cell Physiol Biochem 46(4):1423–1438. https://doi.org/10.1159/000489184 CrossRefPubMed

12.

Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, Zaher W, Mortensen LJ, Alt C, Turcotte R, Yusuf R, Cote D, Vinogradov SA, Scadden DT, Lin CP (2014) Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 508(7495):269–273. https://doi.org/10.1038/nature13034 CrossRef

13.

Johnson RW, Sowder ME, Giaccia AJ (2017) Hypoxia and bone metastatic disease. Curr Osteoporos Rep 7:1–8. https://doi.org/10.1007/s11914-017-0378-8 CrossRef

14.

Araos J, Sleeman JP, Garvalov BK (2018) The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies. Clin Exp Metastasis 35(7):563–599. https://doi.org/10.1007/s10585-018-9930-x CrossRefPubMed

15.

Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Can Res 67(9):4157–4163. https://doi.org/10.1158/0008-5472.CAN-06-2355 CrossRef

16.

Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L (2013) Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 27(8):1697–1706. https://doi.org/10.1038/leu.2013.24 CrossRefPubMed

17.

Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Jin KK, Patel LR, Chi Y, Ziegler AM (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Investig 121(4):1298–1312CrossRef

18.

Jeong HM, Cho SW, Park SI (2016) Osteoblasts are the centerpiece of the metastatic bone microenvironment. Endocrinol Metab 31 4): 485 – 92. https://doi.org/10.3803/EnM.2016.31.4.485 CrossRef

19.

Han Y, You X, Xing W, Zhang Z, Zou W (2018) Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. https://doi.org/10.1038/s41413-018-0019-6

20.

Ruan SS, Li RC, Han Y, Liu J, Li GL, Song YQ, Wu G (2014) Expression and clinical significance of Semaphorin4D in non-small cell lung cancer and its impact on malignant behaviors of A549 lung cancer cells. J Huazhong Univ Sci Technol 34(4):491–496. https://doi.org/10.1007/s11596-014-1304-2 CrossRef

21.

Potiron VA, Roche J, Drabkin HA (2009) Semaphorins and their receptors in lung cancer. Cancer Lett 273(1):1. https://doi.org/10.1016/j.canlet.2008.05.032 CrossRefPubMed

22.

Jiang H, Chen C, Sun Q, Wu J, Qiu L, Gao C, Liu W, Yang J, Nie J, Dong J (2016) The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer. Oncotargets Ther 9:5737–5750. https://doi.org/10.2147/OTT.S114708 CrossRef

23.

Ch’Ng ES, Kumanogoh A (2010) Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer 9(1):251. https://doi.org/10.1186/1476-4598-9-251 CrossRefPubMedPubMedCentral

24.

Zhou H, Yang YH, Binmadi NO, Proia P, Basile JR (2012) The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. Exp Cell Res 318(14):1685–1698. https://doi.org/10.1016/j.yexcr.2012.04.019 CrossRefPubMedPubMedCentral

25.

Sun Q, Zhou H, Binmadi NO, Basile JR (2011) Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem 284(46):32066. https://doi.org/10.1074/jbc.M109.057166 CrossRef

26.

Ying C, Lei Z, Yi P, Ren X, Quan H (2012) Over-expression of semaphorin4D, hypoxia-inducible factor-1α and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. Int J Mol Sci 13(10):13264. https://doi.org/10.3390/ijms131013264 CrossRef

27.

T N-K MS, RH NKHBTK F, H T (2011) Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 17(11):1473–1480. https://doi.org/10.1038/nm.2489 CrossRef

28.

Zhang Y, Wei L, Miron RJ, Shi B, Bian Z (2016) Bone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defects. Sci Rep 6:26925CrossRef

29.

Zhang Y, Wei L, Miron RJ, Shi B, Bian Z (2015) Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with semaphorin 4D expression. J Bone Miner Res 30(2):286–296. https://doi.org/10.1002/jbmr.2322 CrossRefPubMed

30.

Terpos E, Ntanasisstathopoulos I, Christoulas D, Bagratuni T, Bakogeorgos M, Gavriatopoulou M, Eleutherakispapaiakovou E, Kanellias N, Kastritis E, Dimopoulos MA (2018) Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer J. https://doi.org/10.1038/s41408-018-0075-6

31.

Yang YH, Buhamrah A, Schneider A, Lin YL, Zhou H, Bugshan A, Basile JR (2016) Semaphorin 4D promotes skeletal metastasis in breast cancer. Plos ONE 11(2):e0150151. https://doi.org/10.1371/journal.pone.0150151 CrossRefPubMedPubMedCentral

32.

Hu F, Deng X, Yang X, Jin H, Gu D, Lv X, Wang C, Zhang Y, Huo X, Shen Q (2015) Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma. Oncogene 34(49):6007–6017. https://doi.org/10.1038/onc.2015.49 CrossRefPubMed

33.

Sun Q, Zhou H, Binmadi NO, Basile JR (2009) Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem 284(46):32066–32074. https://doi.org/10.1074/jbc.M109.057166 CrossRefPubMedPubMedCentral

34.

Elhabazi A, Delaire S, Bensussan A, Boumsell L, Bismuth G (2001) Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis. J Immunol 166(7):4341–4347CrossRef

35.

Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H (2007) Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci USA 104(5):1621–1626. https://doi.org/10.1073/pnas.0606344104 CrossRefPubMed

36.

Maleki KT, Cornillet M, Bjorkstrom NK (2016) Soluble SEMA4D/CD100: a novel immunoregulator in infectious and inflammatory diseases. Clin Immunol (Orlando Fla) 163:52–59. https://doi.org/10.1016/j.clim.2015.12.012 CrossRef

37.

Chen T, Xu DZ, Li Q, Mou P, Zeng Z, Brass LF, Zhu L (2016) The regulation of Sema4D exodomain shedding by protein kinase A in platelets. Platelets 27(7):673. https://doi.org/10.3109/09537104.2016.1154141 CrossRefPubMed

38.

Mark E, Yibin K (2014) Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther 141(2):222–233. https://doi.org/10.1016/j.pharmthera.2013.10.006 CrossRef

39.

Rahim F, Hajizamani S, Mortaz E, Ahmadzadeh A, Shahjahani M, Shahrabi S, Saki N (2014) Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res 2014(4):405920. https://doi.org/10.1155/2014/405920 CrossRefPubMedPubMedCentral

40.

Liu F, Shen W, Qiu H, Hu X, Zhang C, Chu T (2015) Prostate cancer cells induce osteoblastic differentiation via semaphorin 3A. Prostate 75(4):370–380. https://doi.org/10.1002/pros.22923 CrossRefPubMed

41.

Wang LM, Zhao N, Zhang J, Sun QF, Yang CZ, Yang PS (2018) Tumor necrosis factor-alpha inhibits osteogenic differentiation of pre-osteoblasts by downregulation of EphB4 signaling via activated nuclear factor-kappaB signaling pathway. 53(1): 66–72. https://doi.org/10.1111/jre.12488

42.

JS RLLUBGMCYS, CM C, JC D K (2015) High Glucose Up-regulates ADAM17 through HIF-1α in Mesangial Cells. J Biol Chem 290(35):21603–21614. https://doi.org/10.1074/jbc.M115.651604 CrossRef

43.

Charbonneau M, Harper K, Grondin F, Pelmus M, Mcdonald PP, Dubois CM (2007) Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells. J Biol Chem 282(46):33714. https://doi.org/10.1074/jbc.M704041200 CrossRefPubMed

44.

Rzymski T, Petry A, Kračun D, Riess F, Pike L, Harris AL, Görlach A (2012) The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene 31(31):3621. https://doi.org/10.1038/onc.2011.522 CrossRefPubMed

45.

Lin Q, Cong X, Yun Z (2011) Differential hypoxic regulation of hypoxia-inducible factors 1alpha and 2alpha. Mol Cancer Res 9(6):757. https://doi.org/10.1158/1541-7786.MCR-11-0053 CrossRefPubMedPubMedCentral

46.

Z PM, X ZQLXL, KM X, C W, LF RRL B, L Z (2013) Identification of a calmodulin-binding domain in Sema4D that regulates its exodomain shedding in platelets. Blood 121(20):4221–4230. https://doi.org/10.1182/blood-2012-11-470609 CrossRef

47.

Mou P, Zeng Z, Li Q, Liu X, Xin X, Wannemacher KM, Ruan C, Li R, Brass LF, Zhu L (2013) Identification of a calmodulin-binding domain in Sema4D that regulates its exodomain shedding in platelets. Blood 121(20):4221–4230. https://doi.org/10.1182/blood-2012-11-470609 CrossRefPubMedPubMedCentral

48.

Black RA (1997) A metalloproteinase disintegrin that releases tumour-necrosisi factor-α from cells. Nature. https://doi.org/10.1038/385729a0

49.

Zhou BBS, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10(1):39–50. https://doi.org/10.1016/j.ccr.2006.05.024 CrossRefPubMedPubMedCentral

50.

Xu P, Derynck R (2010) Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell 37(4): 551–566. https://doi.org/10.1016/j.molcel.2010.01.034

51.

Sharma A, Bender S, Zimmermann M, Riesterer O, Broggini-Tenzer A, Pruschy MN (2016) Secretome signature identifies ADAM17 as novel target for radiosensitization of non-small cell lung cancer. Clin Cancer Res 22(17):4428–4439. https://doi.org/10.1158/1078-0432.ccr-15-2449 CrossRefPubMed

52.

Ni SS, Zhang J, Zhao WL, Dong XC, Wang JL (2013) ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival. Tumour Biol 34(3):1813–1818. https://doi.org/10.1007/s13277-013-0721-3 CrossRefPubMed

53.

Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, Tamagnone L, Giordano S (2008) Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 205(7):1673–1685. https://doi.org/10.1084/jem.20072602 CrossRefPubMedPubMedCentral

54.

Yoshida Y, Ogata A, Kang S, Ebina K, Shi K, Nojima S, Kimura T, Ito D, Morimoto K, Nishide M (2015) Semaphorin 4D contributes to rheumatoid arthritis by inducing inflammatory cytokine production: pathogenic and therapeutic implications. Arthritis Rheumatol 67(6):1481–1490. https://doi.org/10.1002/art.39086 CrossRefPubMedPubMedCentral

55.

Johnson RW, Schipani E, Giaccia AJ (2015) HIF targets in bone remodeling and metastatic disease. Pharmacol Ther 150:169–177. https://doi.org/10.1016/j.pharmthera.2015.02.002

56.

Zhang Y, Wei L, Miron RJ, Zhang Q, Bian Z (2014) Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d. J Dent Res 93(11):1095–1100. https://doi.org/10.1177/0022034514552676 CrossRefPubMedPubMedCentral

Title: Sema4D expression and secretion are increased by HIF-1α and inhibit osteogenesis in bone metastases of lung cancer
Authors: Wu-gui Chen
Jing Sun
Wei-wei Shen
Si-zhen Yang
Ying Zhang
Xu Hu
Hao Qiu
Shang-cheng Xu
Tong-wei Chu
Publication date: 01-02-2019
Publisher: Springer Netherlands
Keywords: Lung Cancer
Metastasis
Lung Cancer
Bone Metastasis
Lung Cancer
Published in: Clinical & Experimental Metastasis / Issue 1/2019
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9951-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases

Correction to: The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity

Metastasis in the wild: investigating metastasis in non-laboratory animals

Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases

Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: an overview

Keynote webinar | Spotlight on antibody–drug conjugates in cancer